Skip to content

Studies of Femara at lower dosages?

Page last modified on: October 13, 2008
Question from Susie: Are there any ongoing studies for Femara at lower doses?
Answer —Ruth Oratz, M.D., F.A.C.P.: No. We've done many clinical trials with all of the aromatase inhibitors, and the current doses that are approved and in clinical use have been carefully delineated in large clinical trials.

On Wednesday, September 20, 2006, our Ask-the-Expert Online Conference was called Open for Your Questions. Ruth Oratz, M.D., F.A.C.P. and moderator Beth Baughman DuPree, M.D., F.A.C.S. answered your questions covering a wide variety of issues relating to breast cancer.


The materials presented in these conferences do not necessarily reflect the views of breastcancer.org. A qualified healthcare professional should be consulted before using any therapeutic product or regimen discussed. All readers should verify all information and data before employing any therapies described here.

A production of LiveWorld, Inc.
Copyright 2008. All rights reserved.

Email Updates

Stay informed about current research, online events, and more.

Please leave this field empty

Meet the Experts

Ruth Oratz, M.D., F.A.C.P.Ruth Oratz, M.D., F.A.C.P. is associate professor of clinical medicine at New York University School of Medicine. She is the founder of The Women's Oncology & Wellness Practice in New York City where she specializes in treating women with breast cancer and other malignancies, as well as women at risk for cancer. 

Beth Baughman DuPree, M.D., F.A.C.S.Beth Baughman DuPree, M.D., F.A.C.S. is a general surgeon. Her clinical practice is located at Holy Redeemer Hospital and St. Mary Medical Center.

Back to top

Breastcancer.org 7 East Lancaster Avenue, 3rd Floor Ardmore, PA 19003

Learn more about our commitment to your privacy

© 2009 Breastcancer.org - All rights reserved.

Breastcancer.org is a non-profit organization dedicated to providing information and community to those touched by this disease. Learn more about our commitment to providing complete, accurate, and private breast cancer information.